Recall: Atovaquone
Apr. 2023Pharmacy Updates
Camber Pharmaceuticals Inc. is recalling Atovaquone Oral Suspension, USP 750 mg/5 mL, lot #E220182 with an expiration date of 12/2023, due to possible bacterial contamination in the product. This drug is used for the prevention and treatment of a lung infection called Pneumocystis jiroveci pneumonia (PCP) in adults and children 13 years old and older who cannot tolerate other medicines, such as trimethoprim-sulfamethoxazole. Read the full text of the Atovaquone recall.
Recent Announcements
Important information regarding Medicare GLP-1 Bridge through CMS
The Centers for Medicare & Medicaid Services (CMS) is expanding access to certain GLP-1 medications through the Medicare GLP-1 Bridge short-term demonstration starting July 1, 2026.Jun. 2026Important Notices
CME/CEU Webinar: Bright Beginnings: The Role of Medical and Dental Providers in Early Oral Health
Please join us for a live, CME-accredited and CEU-accredited webinar on Monday, Aug. 24 from noon to 1 p.m., that will educate providers on the importance of early childhood oral health.Jun. 2026Education/Webinars
Provider OnLine Multi-Factor Authentication Enhancements coming soon
Microsoft changes and security enhancements will soon require Provider OnLine users to complete multi-factor authentication (MFA) each time they log in to access the portal. MFA is a security feature that adds an extra layer of protection by requiring more than just a password. This MFA requirement is expected to take effect on June 25, 2026.Jun. 2026Important Notices